Addition of the PD-L1 inhibitor atezolizumab to chemotherapy plus bevacizumab showed little or no benefit in the relapsed setting, echoing previous data from front-line therapy 

The PARP inhibitor shows durable clinical benefits in HRD+ patients with advanced disease reinforcing the importance of testing for BRCA mutations and/or HRD status.

The Society takes a further step toward improving oncologists’ knowledge on healthy lifestyles to better support their patients and reduce the burden of cancer 

The annual ESMO Congress returns to be an onsite event after two years of COVID-19 pandemic, offering attendees opportunities to share knowledge on how to integrate molecular and digital tools into oncology 

At the ESMO Women for Oncology Forum, international experts will discuss the latest data on female representation in the field 

Finding the best treatment strategy for patient subpopulations and adequate funding are key to further advancing the field, says ESMO Award 2022 recipient Prof. Karim Fizazi  

However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community

According to this year’s ESMO Women for Oncology awardee Prof. Fatima Cardoso, steps forward in gender equality have been made, but progress is still slow 

Up to 90% of patients will die from metastatic disease and the search for biomarkers lags behind other tumour types, says ESMO Lifetime Achievement Award 2022 winner Prof. Bernard Escudier